World Pharma News

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure

AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the worsening of heart failure (defined as hospitalisation or an urgent heart failure visit), compared to placebo. The trial was conducted in patients with reduced ejection fraction (HFrEF) on standard of care treatment, including those with and without type-2 diabetes.

The safety profile of Farxiga in the DAPA-HF trial was consistent with the well-established safety profile of the medicine.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “With the DAPA-HF trial, Farxiga becomes the first in its class to demonstrate efficacy and safety data for the treatment of patients with heart failure, with and without type-2 diabetes, on top of standard of care. Today, half of heart failure patients will die within five years of diagnosis and it remains one of the leading causes of hospitalisation. We look forward to discussing the results of DAPA-HF with health authorities as soon as possible.”

John McMurray, MD, University of Glasgow, Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences said: “The benefits of dapagliflozin in DAPA-HF are very impressive, with a substantial reduction in the primary composite outcome of cardiovascular death or hospital admission. We hope these exciting new findings will ultimately help reduce the terrible burden of disease caused by heart failure and help improve outcomes for our patients.”

DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor investigating the treatment of heart failure in adults with HFrEF on top of standard of care (which includes medicines such as angiotensin-converting enzyme [ACE] inhibitors, angiotensin II receptor blockers [ARB], beta blockers, mineralocorticoid-receptor antagonists [MRAs] and neprilysin inhibitors), in patients with and without type-2 diabetes.

The full DAPA-HF trial results will be submitted for presentation at a forthcoming medical meeting.

Farxiga is also being studied in patients with heart failure with preserved ejection fraction (HFpEF) in the DELIVER and DETERMINE (HFrEF and HFpEF) trials.

 

ΠΗΓΗ

Διαβάστε όλες τις τελευταίες Ειδήσεις για την υγεία από την Ελλάδα και τον Κόσμο
Ακολουθήστε το healthweb.gr στο Google News και μάθετε πρώτοι όλες τις ειδήσεις

Διαβάστε Eπίσης:

Hardo Fischer exclusively on healthweb: Gene therapies introduce new therapeutic model in Medicine

‘AeroNabs’ promise powerful, inhalable protection against COVID-19

svg%3E svg%3E
svg%3E
svg%3E
Περισσότερα

The Health Economy: A Strengthening and Stabilizing factor for Economic Development

Dr. Emmanuel Alexandrakis is a Global Market Strategist at the WifOR Institute, a German independent Economic Research Organization, and Adjunct Professor at the MBA International Program of the Athens University of Economics and Business for Health Sector Strategy. The recent global crisis, that was triggered by the COVID-19 pandemic, underlined the importance of investing in the health sector. The unprecedented effects of this global pandemic, […]

How risky is it to attend a Trump campaign rally during a pandemic?

As the coronavirus plows through the United States, health experts worry President Donald Trump’s campaign rally in Tulsa, Oklahoma, will become a new hotspot for coronavirus infections. Leaders and public health experts have expressed concern, including Dr. Anthony Fauci, the nation’s top infectious disease expert, as well as Bruce Dart, the director of Tulsa’s health […]

Trump officials deflect blame for US death toll, escalate reopening push

Analysis by Stephen Collinson, CNN N)Two of President Donald Trump’s top officials are now pointing the finger at the administration’s own scientists and Americans’ pre-existing health conditions to explain the country’s world-leading Covid-19 death toll. Health and Human Services Secretary Alex Azar suggested Sunday that underlying health conditions, including among minorities, were one reason for the high American […]

Coronavirus Q&As for Consumers

The FDA is working to address the coronavirus disease (COVID-19) outbreak and keep you and your family informed on the latest developments. Here are answers to some frequently asked questions from consumers about treatments and prevention:   Q: Are antibiotics effective in preventing or treating COVID-19?   A: No. Antibiotics do not work against viruses; […]

Trump bans export of coronavirus protection gear, says he’s ‘not happy with 3M’

President Donald Trump on Friday invoked the Defense Production Act to ban “unscrupulous actors and profiteers” from exporting critical medical gear used to protect wearers from the coronavirus. The president unveiled the new order amid a dispute with U.S. manufacturing giant 3M, which had warned the Trump administration that halting its exports of respirator masks could make them even […]

WHO warns of global medical equipment shortage as world braces for coronavirus spread

Countries worldwide are preparing for the possibility of public health emergencies related to the novel coronavirus, as the World Health Organization warned a shortage of protective equipment is hampering the response to the outbreak. The virus has infected more than 92,800 people and killed at least 3,200 since it was first identified in the Chinese […]

Scottish Academy launches ‘bold’ strategic priorities

by Anna Smith The Academy of Medical Royal Colleges and Faculties in Scotland (the Scottish Academy) has published its strategic priorities to 2023, outlining a focus on collaborative working between the different medical professions in Scotland, to “improve quality of care for patients.” The Academy, which promotes and co-ordinates the work of the Medical Royal Colleges […]

MHRA updates Dysport license to include upper limb spasticity in children

By Anna Smith The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Ipsen a licence update for Dysport (abobotulinumtoxinA), extending the use of the drug to focal spasticity of upper limbs in paediatric cerebral palsy (CP) patients, two years of age or older. The regulatory body says that the approval was based on a […]